These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39353206)

  • 1. Enhancing Bioavailability: Advances in Oral Isotretinoin Formulations.
    Michael K; Tan J
    Skin Therapy Lett; 2024 Sep; 29(5):10-12. PubMed ID: 39353206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Pharmacokinetic Profiles of a Novel Low-dose Micronized-isotretinoin 32 mg Formulation and Lidose-isotretinoin 40 mg in Fed and Fasted Conditions: Two Open-label, Randomized, Crossover Studies in Healthy Adult Participants.
    Madan S; Kumar S; Segal J
    Acta Derm Venereol; 2020 Feb; 100(4):adv00049. PubMed ID: 31774544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving bioavailability with a novel isotretinoin formulation (isotretinoin-Lidose).
    Tan J; Knezevic S
    Skin Therapy Lett; 2013; 18(6):1-3. PubMed ID: 24305729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARTICLE: Advances in Oral Isotretinoin Therapy.
    Jones M; Armstrong AW; Baldwin H; Stein Gold L; Kircik LH
    J Drugs Dermatol; 2021 May; 20(5):s5-s11. PubMed ID: 33938693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus Statements on the Use of Novel Formulations of Isotretinoin: A Modified Delphi Process.
    Kingston P; Kircik L; Bhatia N; Del Rosso J; Desai SR; Harper JC; Gold LS; Hougeir F; Armstrong AW
    J Drugs Dermatol; 2024 Jun; 23(6):429-432. PubMed ID: 38834212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study.
    Webster GF; Leyden JJ; Gross JA
    J Am Acad Dermatol; 2013 Nov; 69(5):762-767. PubMed ID: 23953888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.
    Webster GF; Leyden JJ; Gross JA
    J Drugs Dermatol; 2014 Jun; 13(6):665-70. PubMed ID: 24918555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for Use of Micronized Isotretinoin for Treatment of Acne Vulgaris: Practical Considerations and Therapeutic Advantages.
    Del Rosso JQ
    J Clin Aesthet Dermatol; 2023 Sep; 16(9):20-24. PubMed ID: 37720199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin.
    Strauss JS; Leyden JJ; Lucky AW; Lookingbill DP; Drake LA; Hanifin JM; Lowe NJ; Jones TM; Stewart DM; Jarratt MT; Katz I; Pariser DM; Pariser RJ; Tschen E; Chalker DK; Rafal ES; Savin RP; Roth HL; Chang LK; Baginski DJ; Kempers S; McLane J; Eberhardt D; Leach EE; Bryce G; Hong J
    J Am Acad Dermatol; 2001 Aug; 45(2):196-207. PubMed ID: 11464180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne.
    Strauss JS; Leyden JJ; Lucky AW; Lookingbill DP; Drake LA; Hanifin JM; Lowe NJ; Jones TM; Stewart DM; Jarratt MT; Katz I; Pariser DM; Pariser RJ; Tschen E; Chalker DK; Rafal ES; Savin RP; Roth HL; Chang LK; Baginski DJ; Kempers S; McLane J; Eberhardt D; Leach EE; Bryce G; Hong J
    J Am Acad Dermatol; 2001 Aug; 45(2):187-95. PubMed ID: 11464179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABSORICA (isotretinoin): a new form.
    Scheinfeld N
    Skinmed; 2013; 11(2):117-9. PubMed ID: 23745231
    [No Abstract]   [Full Text] [Related]  

  • 12. New Formulations of Isotretinoin for Acne Treatment: Expanded Options and Clinical Implications.
    Bellomo R; Brunner M; Tadjally E
    J Clin Aesthet Dermatol; 2021 Dec; 14(12 Suppl 1):S18-S23. PubMed ID: 35291260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Isotretinoin: New Developments Relevant to Clinical Practice.
    Tan J; Boyal S; Desai K; Knezevic S
    Dermatol Clin; 2016 Apr; 34(2):175-84. PubMed ID: 27015777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral isotretinoin for acne.
    Costa CS; Bagatin E; Martimbianco ALC; da Silva EM; Lúcio MM; Magin P; Riera R
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD009435. PubMed ID: 30484286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin.
    Ahmad HM
    Dermatol Ther; 2015; 28(3):151-7. PubMed ID: 25754162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Evidence for Acne Remission With Oral Isotretinoin Cumulative Dosing of 120-150 mg/kg.
    Tan J; Knezevic S; Boyal S; Waterman B; Janik T
    J Cutan Med Surg; 2016 Jan; 20(1):13-20. PubMed ID: 26187395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of nanotechnology, hepato-protective agents in reducing the toxicity and augmenting the bioavailability of isotretinoin.
    Hosny KM; Alhakamy NA; Al Nahyah KS
    Drug Deliv; 2021 Dec; 28(1):123-133. PubMed ID: 33355019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What's new in acne and rosacea?
    Keri J
    Semin Cutan Med Surg; 2016 Jun; 35(2):103-6. PubMed ID: 27416316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is oral isotretinoin the treatment of choice in moderate and severe inflammatory acne vulgaris?
    Verros CD; Rallis E
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1270-1. PubMed ID: 17894728
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness Of Oral Omega 3 In Reducing Mucocutaneous Side Effects Of Oral Isotretinoin In Patients With Acne Vulgaris.
    Zainab Z; Malik NA; Obaid S; Malik S; Aftab K; Mumtaz M; Pervez A; Syed Z
    J Ayub Med Coll Abbottabad; 2021; 33(1):60-63. PubMed ID: 33774956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.